VRCA
Verrica Pharmaceuticals Inc

2,300
Mkt Cap
$93.62M
Volume
401,501.00
52W High
$9.82
52W Low
$3.28
PE Ratio
-3.39
VRCA Fundamentals
Price
$5.45
Prev Close
$5.80
Open
$5.76
50D MA
$6.49
Beta
0.53
Avg. Volume
139,862.83
EPS (Annual)
-$1.68
P/B
3.78
Rev/Employee
$468,118.42
$60.01
Loading...
Loading...
News
all
press releases
VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Verrica Pharmaceuticals Inc. (Verrica or the Company) (NASDAQ...
Business Wire·2d ago
News Placeholder
More News
News Placeholder
VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. VRCA
Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA...
Business Wire·2d ago
News Placeholder
Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. VRCA
Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA...
Business Wire·3d ago
News Placeholder
Verrica Pharmaceuticals Q4 Earnings Call Highlights
Verrica Pharmaceuticals (NASDAQ:VRCA) used its fourth quarter and year-end 2025 corporate update call to highlight what management described as a fundamental business transformation driven by sharper...
MarketBeat·11d ago
News Placeholder
Verrica Pharmaceuticals (NASDAQ:VRCA) Announces Quarterly Earnings Results
Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the...
MarketBeat·11d ago
News Placeholder
Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded by Zacks Research to Hold
Zacks Research lowered shares of Verrica Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Monday...
MarketBeat·11d ago
News Placeholder
Verrica Pharmaceuticals (VRCA) Projected to Post Quarterly Earnings on Tuesday
Verrica Pharmaceuticals (NASDAQ:VRCA) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 10. (View Earnings Report at...
MarketBeat·20d ago
News Placeholder
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Moderate Buy" by Brokerages
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the six analysts that are currently covering the firm, MarketBeat reports...
MarketBeat·25d ago
News Placeholder
Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded to Hold Rating by Wall Street Zen
Wall Street Zen cut shares of Verrica Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday...
MarketBeat·1mo ago
News Placeholder
Verrica Pharmaceuticals (VRCA) Upgraded to Strong Buy: Here's Why
Verrica Pharmaceuticals (VRCA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks·2mo ago
<
1
2
...
>

Latest VRCA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.